These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11224347)

  • 21. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
    Zalewska-Kaszubska J; Gorska D; Dyr W; Czarnecka E
    Physiol Behav; 2008 Mar; 93(4-5):1005-10. PubMed ID: 18262210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone.
    Zalewska-Kaszubska J; Gorska D; Dyr W; Czarnecka E
    Pharmacol Biochem Behav; 2006 Sep; 85(1):155-9. PubMed ID: 16934320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethanol impairs saccadic and smooth pursuit eye movements without producing self-reports of sedation.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 1999 Apr; 23(4):664-72. PubMed ID: 10235302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
    Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
    Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of varying ethanol dose on cigarette consumption in healthy normal volunteers.
    Mitchell SH; de Wit H; Zacny JP
    Behav Pharmacol; 1995 Jun; 6(4):359-365. PubMed ID: 11224344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated cortisol response to alcohol in heavy social drinkers.
    King A; Munisamy G; de Wit H; Lin S
    Int J Psychophysiol; 2006 Mar; 59(3):203-9. PubMed ID: 16359745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcohol choice and amphetamine effects in light and moderate drinkers.
    Stoops WW; Fillmore MT; Poonacha MS; Kingery JE; Rush CR
    Alcohol Clin Exp Res; 2003 May; 27(5):804-11. PubMed ID: 12766625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biphasic alcohol response differs in heavy versus light drinkers.
    King AC; Houle T; de Wit H; Holdstock L; Schuster A
    Alcohol Clin Exp Res; 2002 Jun; 26(6):827-35. PubMed ID: 12068251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers.
    Doty P; Zacny JP; de Wit H
    Behav Pharmacol; 1994 Aug; 5(4 And 5):461-469. PubMed ID: 11224298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.
    Balldin J; Berglund M; Borg S; Månsson M; Bendtsen P; Franck J; Gustafsson L; Halldin J; Nilsson LH; Stolt G; Willander A
    Alcohol Clin Exp Res; 2003 Jul; 27(7):1142-9. PubMed ID: 12878920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
    Zacny JP
    Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naltrexone-induced alterations in human ethanol intoxication.
    Swift RM; Whelihan W; Kuznetsov O; Buongiorno G; Hsuing H
    Am J Psychiatry; 1994 Oct; 151(10):1463-7. PubMed ID: 8092339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethanol palatability and consumption by high ethanol-drinking rats: manipulation of the opioid system with naltrexone.
    Coonfield DL; Kiefer SW; Ferraro FM; Sinclair JD
    Behav Neurosci; 2004 Oct; 118(5):1089-96. PubMed ID: 15506891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of alcohol on polysomnographically recorded sleep in healthy subjects.
    Feige B; Gann H; Brueck R; Hornyak M; Litsch S; Hohagen F; Riemann D
    Alcohol Clin Exp Res; 2006 Sep; 30(9):1527-37. PubMed ID: 16930215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of prostaglandin synthesis and effects of ethanol and pentobarbital in humans.
    Pickworth WB; Fant RV; Henningfield JE
    J Pharmacol Exp Ther; 1997 Oct; 283(1):274-80. PubMed ID: 9336333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An opioid receptor antagonist, naltrexone, does not alter taste and smell responses in humans.
    Scińska A; Koroś E; Polanowska E; Kukwa A; Bogucka-Bonikowska A; Kostowski W; Habrat B; Bieńkowski P
    Pol J Pharmacol; 2000; 52(5):397-402. PubMed ID: 11334233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake.
    Mhatre M; Pruthi R; Hensley K; Holloway F
    Eur J Pharmacol; 2004 May; 491(2-3):149-56. PubMed ID: 15140631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol.
    Mitchell JM; Bergren LJ; Chen KS; Rowbotham MC; Fields HL
    Neurobiol Dis; 2009 Jan; 33(1):72-80. PubMed ID: 18955144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.